Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of rovalpituzumab tesirine versus topotecan in DLL3-high relapsed small cell lung cancer after first-line platinum therapy
CTR20181228Phase 3Suspended
- Sponsor
- AbbVie Inc.
- Start
- May 2017
- Modality
- Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of rovalpituzumab tesirine, topotecan in small cell lung cancer (SCLC), sponsored by AbbVie Inc.. Started May 2017; status: suspended.
02
Drugs
rovalpituzumab tesirinetopotecan
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on CTR20181228.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20181228.